Contextual Genomics appoints Board member Sue Paish as Chair of its Board of Directors

– CANADA, Vancouver –  Contextual Genomics, today announced that Sue Paish will become the new Chair of the Company’s Board of Directors effective May 1, 2019. Mr. Chris Wagner will be stepping down from his role as Chair but will remain as a Director.

“Sue’s proven experience in strategic growth within the healthcare industry will aid Contextual Genomics as we continue to advance our portfolio of end-to-end assays and informatics solutions for cancer testing designed for rapid deployment into labs” said Michael Ball, CEO, Contextual Genomics.

“Sue’s business acumen and knowledge of the diagnostics market will benefit Contextual Genomics’ efforts to enable our partner laboratories to provide access to high quality and affordable genomic testing worldwide.”`

About Sue Paish

Ms. Paish joined the Company’s Board of Directors in 2018 and is the former President and CEO of LifeLabs Medical Laboratory Services.

Ms. Paish brings over two decades of growth-focused executive experience across multiple industries to this role. During her tenure at LifeLabs, the company grew to become Canada’s largest community laboratory and leading diagnostic testing provider. She is currently the CEO of the Digital Technology Supercluster, Chair of the Board of Directors of the Business Council of British Columbia and a director of CORIX Group. Prior to her role as CEO of LifeLabs, Ms. Paish was CEO of Pharmasave and Managing Partner of Fasken, a leading Canadian law firm.

“As a member of the Contextual Genomics’ Board for the past year, it’s been a pleasure working with the Company to expand its strategic laboratory partnerships globally,” says Ms. Paish. “The momentum we are seeing around early access to FOLLOW IT, our ctDNA cancer test, will continue to expand our commercial adoption and ultimately move us towards our mission to positively impact cancer treatment.”

About Contextual Genomics

Contextual Genomics develops cost-effective and clinically actionable molecular tests that guide cancer treatment decisions. These customized tests are offered by our partner laboratories around the world with Contextual Genomics conducting cloud-based bioinformatics services via a SaaS model. The collection of data via this robust network of partners and the use of machine-learning tools will allow Contextual Genomics to improve patient care through improved clinical trial enrolment and new treatment algorithms. Contextual Genomics is founded and managed by global leaders in cancer medicine and bioinformatics, who have unparalleled expertise in cancer genomics and the clonal evolution of cancer.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.